- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04524884
Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study
August 21, 2020 updated by: Fudan University
The Efficacy and Safety of Anti-PD-1 Antibody Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study
This study is designed to evaluate the efficacy and safety of the combination of Toripalimab and Surufatinib for Locally Advanced Thyroid Cancer.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Surufatinib (HMPL-012, previously named sulfatinib) is a small-molecule inhibitor targeting vascular endothelial growth factor receptors, fibroblast growth factor receptor 1 and colony-stimulating factor 1 receptor.
A multi-center , opened, Phase II study have identified the efficacy and safety of Surufatinib in advanced medullary thyroid Carcinoma ( MTC) and iodine-refractory differentiated thyroid carcinoma (DTC).Toripalimab is a humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (programmed death-1; PD-1), with potential immune checkpoint inhibitory and antineoplastic activities.
In the present study, we design a single-arm, single center Phase II trial to evaluate the efficacy and safety of the combination of Surufatinib wiht Toripalimab in locally advanced differentiated thyroid cancer as neoadjuvant therapy.
Study Type
Interventional
Enrollment (Anticipated)
10
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yu-Long Wang, MD
- Phone Number: +86-18017317225
- Email: yulongwang@fudan.edu.cn
Study Contact Backup
- Name: Qing-Hai Ji, MD
- Email: headneck@126.com
Study Locations
-
-
-
Shanghai, China, 200032
- 270 Dongan Road, Fudan University Shanghai Cancer Center
-
Contact:
- Yu-Long Wang
- Phone Number: +86-18017317225
- Email: yulongwang@fudan.edu.cn
-
Contact:
- Qing-Hai Ji
- Email: headneck@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The patient volunteered to participate in the study and signed an informed consent form and shows good compliance;
- Age ≥18 years, male or female;
- Pathologically diagnosed locally advanced differentiated thyroid cancer, including papillary thyroid cancer and follicular thyroid cancer;
- Diagnosis of locally advanced disease should meet at least one of the criteria:1)Unresectable locally advanced lesion; 2)Difficult to achieve R0/R1 resection during preoperative assessment; 3)AJCC T4 stage: Primary tumor with invasion or adhesion of at least one of the following structures / organs, including: trachea, esophagus, common carotid artery, larynx, anterior vertebral fascia, brachial plexus;
- Have at least one measurable lesion (RECIST 1.1);
- Eastern Cooperative Oncology Group (ECOG) score 0-2;
- Expected survival time ≥ 12 weeks;
- If the patient presents with distant metastasis, the value of local treatment should be assessed by the investigator;
- The patient volunteered to receive tumor biopsy/surgery during rull-in and rull-out periods.
- The main organ functions meet the following criteria within 7 days before treatment:1)Standard blood test (without blood transfusion within 14 days):Hemoglobin (HB) ≥90g / L; Absolute neutrophil value (ANC) ≥ 1.5 × 109 / L; Platelet (PLT) ≥80 × 109 / L; 2)Biochemical inspection must meet the following standards: Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal value (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 ULN, if with liver metastases, ALT and AST ≤ 5 ULN; Serum creatinine (Cr) ≤ 1.5 ULN or creatinine clearance (CCr)>50ml / min; 3)International normalized ratio (INR) ≤2.3 or prothrombin time (PT) prolongs less than 6 seconds; 4)Urine routine indicates urinary protein <++, and the 24-hour urine protein quantification is less than 1.0 g.
- Women of childbearing age should agree to use contraceptives during the study; negative serum or urine pregnancy tests within 14 days before study enrollment.
Exclusion Criteria:
- History of a second malignancy during the past 5 years before inclusion in the study or during participation in the study, with the exception of a dermal basal cell or squamous cell carcinoma or cervical carcinoma in situ, if these were curatively treated;
- Use any anti-tumor treatment within 4 weeks (28 days) prior to the start of the study treatment, except for TSH suppression treatment;
- Previously used any immune checkpoint inhibitors, including but not limited to pembrolizumab, nivolumab, camrelizumab, sintilimab and etc;
- With other uncontrolled cardiac symptoms or disease;
- Patients whose blood pressure is still unsatisfactory with a blood pressure medication (systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg) or a history of hypertensive encephalopathy or hypertensive crisis;
- Those who have multiple factors (such as inability to swallow) that affect oral medication;
- Patients with a gastrointestinal bleeding tendency including 1)Active peptic ulcer; 2)Fecal occult blood ≥ ++; 3)A history of hematemesis or melena within 3 months;
- Coagulation disorder, such as INR greater than 1.5, or activated partial thromboplastin time (APTT) greater than 1.5 * ULN;
- Significant hemoptysis within 2 months before screening, or the daily volume of hemoptysis reached half a teaspoon (2.5ml) or more;
- Patients whose imaging showed that the tumor had invaded the important blood vessels or the researchers judged that the tumor was likely to invade important blood vessels during the subsequent study period and caused fatal bleeding;
- Arterial / venous thrombosis events, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis and pulmonary embolism within 6 months;
- Patients suffering from interstitial pneumonia or ILD, or with a history of interstitial pneumonia or ILD requiring hormone therapy, or with other pulmonary fibrosis,organic pneumonia(e.g., obliterative bronchiolitis), pneumoconiosis, drug-induced pneumonia and idiopathic pneumonia that may interfere with the diagnosis and management of immune-related pulmonary toxicity; or patients with CT image indicating active pneumonia or severely impaired pulmonary function during screening. Radiation pneumonia is acceptable in the radiation field. Patients with active tuberculosis will be excluded;
- Active autoimmune disease or history of autoimmune disease with recurrence potential (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis): Patients with skin diseases that do not require systemic treatment such as vitiligo, psoriasis, hair loss, controlled type I diabetes receiving insulin therapy; childhood asthma that is completely relieved, or those who do not need any intervention in adulthood can be included; Patients with asthma who undergo medical intervention such as bronchiectasis, cannot be included;
- Use immunosuppressive agents or systemic hormone therapy within preceding 14 days before the study starts to achieve the purpose of immunosuppression (dose>10mg/day prednisone or hormones with equivalent effects);
- Patients who received strong CYP3A4/CYP2C19 inducer including rifampin (and its analogs) and hypericum perforatum or strong CYP3A4/CYP2C19 inhibitor within preceding 14 days;
- Patients who have a history of severe allergies to any monoclonal antibody or anti-angiogenic targeted drugs;
- Patients who have severe uncontrolled infection during study screening;
- Patients who are pregnant or lactating;
- Patients who refuse to receive tumor biopsy during rule-in and rule-out period;
- Other reasons according to the investigator's judgement.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A
Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment.
Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.
After neoadjuvant Toripalimab and Surufatinib treatment, the patients will receive operation treatment if the tumor is evaluated as resectable cases by clinical examination.
|
Surufatinib is a tablet in the form of 50mg, oral, once a day.
Other Names:
Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
Other Names:
|
Experimental: Cohort B
Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment.
Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.
After neoadjuvant Toripalimab and Surufatinib treatment, the patients will receive further drug reatment, if the tumor is evaluated as unresectable cases and patients have potential benefits by clinical examination.
|
Surufatinib is a tablet in the form of 50mg, oral, once a day.
Other Names:
Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
Other Names:
|
Experimental: Cohort C
Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment.
Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.
After neoadjuvant Toripalimab and Surufatinib treatment, the patients will be removed from the study, if the tumor is evaluated as unresectable cases and patients have no potential benefits by clinical examination.
|
Surufatinib is a tablet in the form of 50mg, oral, once a day.
Other Names:
Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: 16 months after the last patient enrolled
|
Objective Response Rate
|
16 months after the last patient enrolled
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
R0/1 resection rate
Time Frame: Within one week after operation
|
R0 and R1 resection rate reviewed by operation team and pathologists
|
Within one week after operation
|
DCR
Time Frame: 16 months after the last patient enrolled
|
Disease Control Rate
|
16 months after the last patient enrolled
|
TTR
Time Frame: 16 months after the last patient enrolled
|
Time to objective response
|
16 months after the last patient enrolled
|
PFS
Time Frame: 16 months after the last patient enrolled
|
Progression Free Survival
|
16 months after the last patient enrolled
|
OS
Time Frame: 16 months after the last patient enrolled
|
Overall Survival
|
16 months after the last patient enrolled
|
AE
Time Frame: From first dose to within 30 days after the last dose
|
adverse events
|
From first dose to within 30 days after the last dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Qing-Hai Ji, MD, Fudan University
- Principal Investigator: Yu-Long Wang, MD, Fudan University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 1, 2020
Primary Completion (Anticipated)
April 30, 2022
Study Completion (Anticipated)
September 30, 2022
Study Registration Dates
First Submitted
August 20, 2020
First Submitted That Met QC Criteria
August 21, 2020
First Posted (Actual)
August 24, 2020
Study Record Updates
Last Update Posted (Actual)
August 24, 2020
Last Update Submitted That Met QC Criteria
August 21, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Thca-NEO-ST
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thyroid Cancer
-
National Cancer Institute (NCI)TerminatedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Anaplastic Thyroid Cancer | Stage III Follicular Thyroid Cancer | Stage III Papillary Thyroid CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI); GlaxoSmithKline; National Comprehensive Cancer...CompletedRecurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
National Cancer Institute (NCI)CompletedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid CancerUnited States
-
University of PennsylvaniaCompletedMetastatic Medullary Thyroid Cancer | Metastatic Differentiated Thyroid Cancer | Metastatic Anaplastic Thyroid Cancer | Metastatic Poorly Differentiated Thyroid CancerUnited States
-
Massachusetts General HospitalEli Lilly and CompanyRecruitingThyroid Carcinoma | Thyroid Cancer | Papillary Thyroid Cancer | Metastatic Thyroid Cancer | Follicular Thyroid Cancer | Unresectable Thyroid Gland CarcinomaUnited States
-
Children's Hospital of PhiladelphiaBayerRecruitingCancer | Pediatric Cancer | Differentiated Thyroid Cancer | Cancer, ThyroidUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Thyroid Gland Medullary Carcinoma | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedThyroid Cancer, Medullary | Thyroid Cancer | Papillary Thyroid Cancer | Differentiated Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid CancerUnited States
Clinical Trials on Surufatinib
-
The Affiliated Hospital of Xuzhou Medical UniversityRecruiting
-
Qilu Hospital of Shandong UniversityThe Affiliated Hospital of Qingdao University; Shandong Provincial Hospital... and other collaboratorsNot yet recruitingNeuroendocrine Tumor Grade 3
-
Qilu Hospital of Shandong UniversityNot yet recruiting
-
Hutchison Medipharma LimitedCompletedHealthyUnited States
-
Zhejiang Cancer HospitalRecruitingBile Duct AdenocarcinomaChina
-
Shanghai Ninth People's Hospital Affiliated to...RecruitingHead and Neck Cancers - Salivary GlandChina
-
Changhai HospitalNot yet recruitingPancreatic Neuroendocrine TumorChina
-
Fudan UniversityNot yet recruitingSoft Tissue Sarcoma Adult
-
Fudan UniversityRecruitingDifferentiated Thyroid CancerChina
-
HutchmedNo longer available